Literature DB >> 7887987

Expression of functional cytochrome P4501A1 in human embryonic hepatic tissues during organogenesis.

H Y Yang1, M J Namkung, M R Juchau.   

Abstract

Investigations with chemical inhibitors and with inhibitory antibodies specific for cytochrome P4501A-catalyzed ethoxyresorufin (ethoxyphenoxazone) O-deethylation and 2-acetylaminofluorene (N-2-fluorenylacetamide) ring hydroxylation indicated that cytochrome(s) P450 of the 1A subfamily was functionally expressed in human embryonic hepatic tissues at very early stages (days 50-60) of gestation. Lack of detectable capacity of hepatic microsomal enzymes to catalyze either N-hydroxylation of 2-acetylaminofluorene or O-demethylation of methoxyresorufin indicated that functional cytochrome P4501A2 is expressed minimally or negligibly in human embryonic hepatic tissues. By contrast, profound inhibition of the ring hydroxylation of 2-acetylaminofluorene and of the O-deethylation of ethoxyresorufin by 7,8-benzoflavone as well as by anti-cytochrome P4501A1 antibodies indicated the presence of significant levels of functional cytochrome P4501A1 in hepatic microsomes of human embryos. Using the reverse transcriptase-linked polymerase chain reaction with specific oligonucleotide primers, we also detected significant expression of cytochrome P4501A1 mRNA in human embryonic livers. Polymerase chain reaction amplification, cloning and sequencing of the corresponding cDNA provided evidence that the cytochrome P4501A1 mRNA expressed in human embryonic tissues was identical to that expressed in adult human tissues. The results of the study have important implications in terms of the embryotoxic effects of chemicals that are known to be substrates, inhibitors or inducers of cytochrome P4501A1 and to which pregnant women are exposed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7887987     DOI: 10.1016/0006-2952(94)00493-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.

Authors:  Ankit Balhara; Aditya R Kumar; Jashvant D Unadkat
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

Review 2.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling.

Authors:  Laura Buyssens; Laura De Clerck; Wim Schelstraete; Maarten Dhaenens; Dieter Deforce; Miriam Ayuso; Chris Van Ginneken; Steven Van Cruchten
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 4.  Ontogeny of Drug-Metabolizing Enzymes.

Authors:  Aarzoo Thakur; Md Masud Parvez; J Steven Leeder; Bhagwat Prasad
Journal:  Methods Mol Biol       Date:  2021

Review 5.  Incorporating children's toxicokinetics into a risk framework.

Authors:  Gary Ginsberg; William Slikker; James Bruckner; Babasaheb Sonawane
Journal:  Environ Health Perspect       Date:  2004-02       Impact factor: 9.031

6.  The human hepatic cell line HepaRG as a possible cell source for the generation of humanized liver TK-NOG mice.

Authors:  Yuichiro Higuchi; Kenji Kawai; Hiroshi Yamazaki; Masato Nakamura; Françoise Bree; Christiane Guguen-Guillouzo; Hiroshi Suemizu
Journal:  Xenobiotica       Date:  2013-09-25       Impact factor: 1.908

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.